c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin–ATP-binding cassette G2 signaling (original) (raw)

• Jemal A, Siegel R, Xu J, Ward E . Cancer statistics 2010 CA Cancer J Clin 2010; 60: 277–300.
  Article PubMed Google Scholar
• Bast RC, Hennessy B, Mills GB . The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009; 9: 415–428.
  Article CAS PubMed PubMed Central Google Scholar
• Bapat SA, Mali AM, Koppikar CB, Kurrey NK . Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005; 65: 3025–3029.
  Article CAS PubMed Google Scholar
• Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006; 103: 11154–11159.
  Article CAS PubMed PubMed Central Google Scholar
• Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68: 4311–4320.
  Article CAS PubMed PubMed Central Google Scholar
• Hu L, McArthur C, Jaffe RB . Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 2010; 102: 1276–1283.
  Article CAS PubMed PubMed Central Google Scholar
• Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE . Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci USA 2011; 108: 6468–6473.
  Article CAS PubMed PubMed Central Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL . Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105–111.
  Article CAS PubMed Google Scholar
• Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC . Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001; 22: 255–288.
  CAS PubMed Google Scholar
• Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003; 98: 758–764.
  Article CAS PubMed Google Scholar
• Raspollini MR, Amunni G, Villanucci A, Baroni G, Taddei A, Taddei GL . c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study. Ann Oncol 2004; 15: 594–597.
  Article CAS PubMed Google Scholar
• Brustmann H . Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecol Oncol 2005; 98: 396–402.
  Article CAS PubMed Google Scholar
• Alberts DS, Liu PY, Wilczynski SP, Jang A, Moon J, Ward JH et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Oncol 2007; 17: 784–788.
  Article CAS Google Scholar
• Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2008; 26: 3418–3425.
  Article CAS PubMed Google Scholar
• Shaw TJ, Vanderhyden BC . AKT mediates the prosurvival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate. Gynecol Oncol 2007; 105: 122–131.
  Article CAS PubMed Google Scholar
• Karlsson MO, Molnar V, Freijs A, Nygren P, Bergh J, Larsson R . Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 1999; 27: 1220–1223.
  CAS PubMed Google Scholar
• Mutch DG, Williams S . Biology of epithelial ovarian cancer. Clin Obstet Gynecol 1994; 37: 406–422.
  Article CAS PubMed Google Scholar
• Wang GL, Semenza GL . Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993; 82: 3610–3615.
  CAS PubMed Google Scholar
• Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275–284.
  Article CAS PubMed Google Scholar
• Fodde R, Brabletz T . Wnt/β-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007; 19: 150–158.
  Article CAS PubMed Google Scholar
• Chien AJ, Conrad WH, Moon RT . A Wnt survival guide: from flies to human disease. J Invest Dermatol 2009; 129: 1614–1627.
  Article CAS PubMed PubMed Central Google Scholar
• Pon YL, Wong AS . Gonadotropin-induced apoptosis in human ovarian surface epithelial cells is associated with cyclooxygenase-2 up-regulation via the beta-catenin/T-cell factor signaling pathway. Mol Endocrinol 2006; 20: 3336–3350.
  Article CAS PubMed Google Scholar
• Molenaar M, van de Watering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V et al. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 1996; 86: 391–399.
  Article CAS PubMed Google Scholar
• Cheon S, Poon R, Yu C, Khoury M, Shenker R, Fish J et al. Prolonged beta-catenin stabilization and TCF-dependent transcriptional activation in hyperplastic cutaneous wounds. Lab Invest 2005; 85: 416–425.
  Article CAS PubMed Google Scholar
• Heinrich M, Dooley DC, Freed AC, Band L, Hoatlin ME, Keeble WW et al. Constitutive expression of steel factor gene by human stromal cells. Blood 1993; 82: 771–783.
  CAS PubMed Google Scholar
• Broudy VC, Kovach NL, Bennett LG, Lin N, Jacobsen FW, Kidd PG . Human umbilical vein endothelial cells display high-affinity c-kit receptors and produce a soluble form of the c-kit receptor. Blood 1994; 83: 2145–2152.
  CAS PubMed Google Scholar
• Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ et al. Phase II trial of imatinib mesylate in patients with recurrent platinum-and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006; 10: 126–131.
  Article Google Scholar
• Posadas EM, Kwitkowski V, Kotz HL, Espina V, Minasian L, Tchabo N et al. A prospective analysis of imatinib-incduced c-kit modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 2007; 110: 309–317.
  Article CAS PubMed Google Scholar
• Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 2008; 113: 723–732.
  Article CAS PubMed Google Scholar
• Deininger M, Buchdunger E, Druker BJ . The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640–2653.
  Article CAS PubMed Google Scholar
• Druker BJ . Efficacy and safety of a specific inhibitor of the Brc-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.
  Article CAS PubMed Google Scholar
• Mundhenke C, Weigel MT, Sturner KH, Roesel F, Meinhold-Heerlein I, Bauerschlag DO et al. Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects. J Cancer Res Clin Oncol 2008; 134: 1397–1405.
  Article CAS PubMed Google Scholar
• Shield K, Ackland ML, Ahmed N, Rice CE . Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol 2009; 113: 143–148.
  Article PubMed Google Scholar
• Luo L, Zeng J, Liang B, Zhao Z, Sun L, Cao D et al. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp Mol Pathol 2011; 91: 596–602.
  Article CAS PubMed Google Scholar
• Sattler M, Salgia R . Targeting c-Kit mutations: basic science to novel therapies. Leuk Res 2004; 28: S11–S20.
  Article CAS PubMed Google Scholar
• Norton L, Massague J . Is cancer a disease of self-seeding? Nat Med 2006; 12: 875–878.
  Article CAS PubMed Google Scholar
• Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G . Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001; 7: 1661–1668.
  CAS PubMed Google Scholar
• Nakayama K, Kanzaki A, Hata K, Katabuchi H, Okamura H, Miyazaki K et al. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett 2002; 176: 215–223.
  Article CAS PubMed Google Scholar
• Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC . Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cells. Cancer Res 1997; 57: 850–856.
  CAS PubMed Google Scholar
• Tetsu O, McCormick F . β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422–426.
  Article CAS PubMed Google Scholar
• Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD . Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 2001; 1520: 234–241.
  Article CAS PubMed Google Scholar
• Scotto KW . Transcriptional regulation of ABC drug transporters. Oncogene 2003; 22: 7496–7511.
  Article CAS PubMed Google Scholar
• Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A . Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. J Clin Pathol 1999; 155: 527–536.
  CAS Google Scholar
• Lee CM, Shvartsman H, Deavers MT, Wang SC, Xia W, Schmandt R et al. β-Catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol 2003; 88: 363–368.
  Article CAS PubMed Google Scholar
• Kildal W, Risberg B, Abeler VM, Kristensen GB, Sudbo J, Nesland JM et al. Beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer 2005; 41: 1127–1134.
  Article CAS PubMed Google Scholar
• Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 2012; 18: 869–881.
  Article CAS PubMed Google Scholar
• Zajchowski DA, Karlan BY, Shawver LK . Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther 2012; 11: 492–502.
  Article CAS PubMed Google Scholar
• Ishitani T, Ninomiya-Tsuji J, Nagai S, Nishita M, Meneghini M, Barker N et al. The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature 1999; 399: 798–802.
  Article CAS PubMed Google Scholar
• Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, Lyons AB et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 2007; 6: 1159–1166.
  Article CAS PubMed Google Scholar
• Wong AS, Gumbiner BM . Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol 2003; 161: 1191–1203.
  Article CAS PubMed PubMed Central Google Scholar